Interstitial lung disease
Author:
Open Access
- 28 February 2013
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 22 (127) , 26-32
Abstract
This article reviews the most important articles published in interstitial lung disease, as reviewed during the Clinical Year in Review session at the 2012 annual European Respiratory Society Congress in Vienna, Austria.Since the recent international guidelines for the management of idiopathic pulmonary fibrosis (IPF), important new evidence is available. The anti-fibrotic drug pirfenidone has been recently approved in Europe. Other pharmacological agents, especially nintedanib, are still being tested. The so-called triple combination therapy, anticoagulation therapy and endothelin receptor antagonists, especially ambrisentan, are either harmful or ineffective in IPF and are not recommended as treatment. Although the clinical course of IPF is highly variable, novel tools have been developed for individual prediction of prognosis. Acute exacerbations of IPF are associated with increased mortality and may occur with higher frequency in IPF patients with associated pulmonary hypertension.Interstitial lung disease associated with connective tissue disease has been definitely established to have a better long-term survival than IPF. A subset of patients present with symptoms and/or biological autoimmune features, but do not fulfil diagnostic criteria for a given autoimmune disease; this condition is associated with a higher prevalence of nonspecific interstitial pneumonia pattern, female sex and younger age, although survival relevance is unclear.Keywords
This publication has 61 references indexed in Scilit:
- The pathogenesis of pulmonary fibrosis: a moving targetEuropean Respiratory Journal, 2012
- Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomesEuropean Respiratory Review, 2012
- Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosisEuropean Respiratory Review, 2012
- An earlier and more confident diagnosis of idiopathic pulmonary fibrosisEuropean Respiratory Review, 2012
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Triple therapy in idiopathic pulmonary fibrosis: an alarming press releaseEuropean Respiratory Journal, 2012
- Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosisEuropean Respiratory Review, 2012
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011